N ecrotizing enterocolitis (NEC)
is a devastating intestinal disease that affects preterm infants. [1] [2] [3] [4] [5] [6] NEC results in ischemia and necrosis of the intestine, which may lead to perforation requiring surgery, as well as significant morbidity and mortality. [1] [2] [3] [4] Common risk factors for NEC include low birth weight, younger gestational age, African-American race, enteral feeding before perforation, and exposure to multiple medications 2, 3 ; these medications include prenatal and postnatal corticosteroids, surfactant, indomethacin, erythropoietin, and possibly caffeine. 4 Currently, the pathophysiology and causes of NEC have not been precisely delineated, but many theories exist.
Neonates with NEC may also have apnea of prematurity and thus require treatment with caffeine citrate. 7, 8 Typically, the use of caffeine citrate requires a loading dose, which is followed 24 hours later Purpose. The results of a case-control study of the potential role of caffeine citrate therapy in the development of necrotizing enterocolitis (NEC) are presented. Methods. Patient records for a 10-year period were reviewed to collect sufficient data to test the hypothesis that newborns treated in a hospital's perinatal intensive care unit for NEC might have had a higher cumulative exposure to caffeine citrate relative to that of neonates of similar postconceptional and postnatal age who did not develop NEC. Ninety-five cases of NEC were identified; each case was matched to a control case by gestational age and birth weight. To enable comparative analyses, each control was assigned an index date according to the number of days from birth to NEC diagnosis in the paired case. Data collected for analysis included patient demographics, information on caffeine citrate and concomitant medication use, and potential confounding factors.
Results. Analysis of aggregated data for the entire seven-day NEC event timeframe indicated no significant differences between cases and controls with regard to average caffeine citrate loading doses (p = 0.5), cumulative exposure (p = 0.2), and trough serum concentrations (p = 0.5); mean cumulative exposure values differed significantly at one time point (four days prior to NEC diagnosis (p = 0.04). Conclusion. Cumulative exposure to caffeine citrate among infants who developed NEC and infants who did not develop NEC differed significantly at only one of six evaluated time points during the seven days before NEC development or the index date. There was no significant difference between groups in the proportions of patients who received caffeine citrate or in mean serum caffeine concentrations. Am J Health-Syst Pharm. 2013; 70:603-8 by a daily maintenance dose. 8 The trough serum caffeine level is usually monitored weekly, and a low trough level may warrant a repeat loading Am J Health-Syst Pharm-Vol 70 Apr 1, 2013 dose of caffeine citrate followed by a change in the maintenance dose. 8 There are limited and conflicting data about the use of caffeine citrate and its impact on the development of NEC 9, 10 ; therefore, an association between caffeine citrate exposure and the development of NEC cannot be dismissed.
We conducted a retrospective, chart-based case-control study to investigate the hypothesis that among neonates born at one institution over a roughly 10-year period, those who developed NEC were more likely to have had greater cumulative caffeine citrate exposure than a control group of patients of similar postconceptional and postnatal age who did not develop NEC. Our secondary hypotheses were that patients with NEC were more likely to have received caffeine, to have received higher caffeine citrate loading doses, and to have higher plasma caffeine levels than matched controls.
Methods
A chart review was conducted to identify all neonates treated in a regional perinatal intensive care unit (ICU) between January 2000 and June 2009 who had a gestational age of ≤34 weeks and had NEC requiring either medical or surgical treatment, as determined according to the staging method of Bell et al. 11 This study was approved by a pediatrics-focused investigational review board at the University at Buffalo. Patient data were extracted from the neonatal ICU patient data system (NeoData, version 4.0.3612, Isoprime Corporation, Lisle, IL) at Women and Children's Hospital of Buffalo. In order to ensure that a complete history was available for each neonate with NEC included in the case-control study, cases were excluded from the analysis if the neonates involved had been transferred from another hospital. The included neonates were matched 1:1 with control patients who did not develop NEC (also identified from the NeoData database) by gestational age, birth weight, birth year, and proximal date of birth. To facilitate the collection of observational data on control cases in relation to the dates of occurrence of cases of NEC, control cases were assigned an index date, calculated by (1) ascertaining the number of days from birth to the diagnosis of each NEC case and then (2) adding the same number of days to the date of birth of the matched control.
The demographic data collected were as follows: date of birth, date of hospital discharge, gestational age at birth and at the time of NEC diagnosis, birth weight, sex, race, and Apgar scores at one and five minutes. The diagnosis of NEC was based on official radiology reports confirming the presence of pneumatosis, portal venous air, or perforation; cases in which patients were diagnosed with spontaneous intestinal perforation were excluded from the analysis. Surgical interventions with or without ostomy were documented. The duration of antibiotic administration was also recorded.
Information on numerous potential confounding factors was collected. Data on indomethacin use (including indication), aminophylline and theophylline use, and antenatal and postnatal corticosteroid use from birth to the date of NEC diagnosis or (for controls) the index date were collected. Data on all medications administered to an infant during the 14 days before NEC diagnosis or the index date were obtained. Information on the number of transfusions per day, the use of parenteral versus enteral nutrition, enteral nutrition caloric density, and episodes of apnea or bradycardia for the 3 days preceding NEC diagnosis or the index date was collected. Blood and urine culture results documented during the 3 days before and the 3 days after NEC diagnosis or the index date were compiled.
For each case and matched control, data were collected on caffeine citrate use during the seven days before NEC diagnosis or the index date, including the indication for use, loading and maintenance doses, oral versus parenteral administration, and serum caffeine levels; from these data, the daily mean caffeine citrate dose was calculated by averaging the mean daily maintenance and loading doses administered to each infant receiving caffeine citrate. Cumulative caffeine citrate exposure was determined by adding the mean caffeine citrate dose on the day of NEC diagnosis or the index date to the prior-day mean dose for each of the seven days before NEC diagnosis or the index date. Caffeine citrate exposure was calculated in this manner to enable analyses to determine if there was an association between NEC development and cumulative caffeine citrate exposure, as infants typically do not receive only one dose of caffeine citrate.
The standard practice at the study institution is to administer a loading dose of caffeine citrate 20-25 mg/kg and start a maintenance dose of 6 mg/kg/day 24 hours after the loading dose. Loading doses may be repeated on the basis of symptoms or inadequate trough levels to reach a target caffeine concentration of 20-25 mg/mL and are not typically weightadjusted. However, administration practices may vary at the discretion of the attending neonatologist.
Through an a priori analysis, it was determined that a total sample of 128 cases would be necessary to achieve 80% power to demonstrate the hypothesized effects, assuming a mean between-group difference in total caffeine citrate exposure of 10% and an S.D. of 20% for the differences between paired observations. The 10% difference in caffeine citrate exposure was based on what was thought to be clinically important.
Patient demographics and clinical characteristics were reported as frequencies. Medical-history variables were reported as mean ± S.D. values for parametric distributions and as median values (with range) for nonparametric distributions. The skewness of the data aided in the decision to use nonparametric tests. Univariate analysis was conducted for all characteristics via chi-square analysis and Fisher's exact test. The independent t test and the Mann-Whitney U test were used to assess the significance of continuous variables. The a priori level of significance was 0.05 in the univariate analysis. A stepwise logistic regression model was used to test each of the study hypotheses in order to adjust for the effects of other independent variables on the primary and secondary outcomes. Variables were considered for inclusion in the model if the associated p value was ≤0.2. Stepping was performed to maximize the significance of the model and included only variables with a p value of ≤0.1. The number of patient cases evaluated via logistic regression was maximized by excluding variables that would result in a reduction in the number of cases included in the model of >25%. Data analysis was performed using Systat, version 13.00.05 (Systat Software, Inc., Chicago, IL).
Results
Ninety-five cases of stage II or stage III NEC during the specified study period were identified; all 95 NEC cases were matched to control cases and included in the analysis. There was no significant difference in the mean ± S.D. birth weight between cases (1.3 ± 0.4 kg) and controls (1.4 ± 0.5 kg) (p = 0.1) or in birth-weight percentile between NEC cases (40.9; range, 0-92.4) and controls (48.1; range, 0.6-95.3) (p = 0.08). The numbers of infants who were small for gestational age (i.e., birth weight in the 10th percentile) differed significantly (p = 0.003) between cases (13 [14%] ) and controls (2 [2%] (Table 2) . After adjusting for other significant variables by logistic regression, cumulative caffeine citrate exposure within four days of the index date was found to be lower among cases versus controls (OR, 0.93; 95% CI, 0.9-1).
There was not a significant difference between case and control patients in mean ± S.D. caffeine citrate loading doses for the seven days leading up to NEC diagnosis or the index date (17.6 ± 11.3 mg/kg in case patients and 19.9 ± 10.1 mg/kg in control patients, p = 0.5). Fifteen patients in the NEC group and 10 patients in the control group received a loading dose or a repeat loading dose of caffeine citrate, with doses ranging from 4.9 to 31.5 mg/kg. When comparing average troughs, there was no statistical difference in mean ± S.D. trough caffeine concentration between case and control patient for the three days before the NEC or index date (19.8 ± 5.5 mg/mL for case patients and 18.4 ± 4.6 mg/mL for control patients, p = 0.5). The numbers of infants receiving i.v. rather than oral caffeine citrate were also not significantly different in the case patients (28 [29%]) and the control patients (23 [24%]) (p = 0.2).
The results of univariate analyses of confounding variables are shown in Table 3 . The frequency of blood transfusions differed significantly between groups, with 20 case (21%) 
Discussion
In our study, there was no significant difference in the proportions of patients who received caffeine citrate in the NEC group compared to the control group. That finding was consistent with the findings in the study by Schmidt et al., 9 who conducted a large randomized control trial to examine safety in infants receiving caffeine citrate versus a placebo and found no difference in the occurrence of NEC. The finding of comparable levels of exposure in the NEC case and control groups was contradictory to our hypothesis-and incongruous with information in the caffeine citrate package insert, which lists NEC as an adverse effect, secondary to a study by Erenberg et al. 10 Additionally, we analyzed caffeine citrate loading doses and caffeine plasma levels but did not find a significant difference between cases and controls. While none of the above caffeine analyses found a statistical difference, our study did find an association between NEC and mean cumulative caffeine citrate exposure, which was higher in the control group four days prior to NEC or the index date.
We do not have a physiological explanation for control patients having greater cumulative caffeine exposure. There have been four different studies published that looked at the physiological effects of caffeine on intestinal arteries. [12] [13] [14] [15] Two of these studies found that a loading dose of caffeine citrate, intravenous or oral, of 50 mg/kg decreased blood flow velocity in splanchnic arteries and reduced intestinal perfusion. 12, 13 Another study found that splitting the loading dose of oral caffeine citrate into two equal doses of 25 mg/kg, separated by four hours, did not significantly affect blood flow velocity in the celiac artery and superior mesenteric artery. 14 In the fourth study, the administration of a 20-mg/kg caffeine citrate i.v. load did not produce a significant decrease in blood flow velocity. 15 Based on the results of two of these studies and the theory that the interruption of intestinal blood flow may be a contributor to NEC development, one might expect-if caffeine citrate exposure were associated with NEC-that such exposure would be greater in infants developing NEC than in those who do not. 2, 12, 13 It is possible that our finding of higher mean cumulative caffeine citrate exposure in the control group may have been coincidental and that other factors such as differences in proportion of patients with low birth-weight percentiles, positive blood cultures, transfusions, and comorbidities could have influenced the occurrence of NEC. Factors that are known to increase the risk of NEC include the use of multiple medications, low birth weight, and the administration of blood transfusions. 2, 3, [16] [17] [18] [19] [20] Our univariate analysis did find that concomitant medication use, positive blood cultures, apnea episodes, low-percentile birth weight, and blood transfusions were significant contributors to NEC. Furthermore, birth weight in the 25th percentile and blood transfusions were significant contributors to NEC risk in the logistic regression model. However, caffeine citrate use has been shown to reduce the frequency of other complications associated with prematurity such as patent ductus arteriosus, retinopathy of prematurity, and cerebral palsy. 9 It is possible that caffeine citrate may exert a protective effect with regard to various complications of prematurity, but the existence of any such effect is not clear at this time.
Our study was not specifically intended to detect an association between blood transfusions and the development of NEC, but such an association was found. We found that case patients were more likely than control patients to have had a blood transfusion in the three days before the development of NEC or the control index date (OR, 3.4) . This data collection period was one day longer than that used by Mally et al., 17 who found an association between blood transfusions and the development of late-onset NEC. In their study of premature infants, Josephson et al. 19 did not find a difference in the frequencies of red blood cell transfusions in NEC patients and control patients, but they found an association between such RBC transfusions and late-onset NEC (i.e., NEC diagnosed at a postnatal age of more than four weeks). Lastly, El-Dib et al. 20 concluded that infants who developed NEC frequently received RBC transfusions in the 48-72 hours before NEC diagnosis.
Our study had several notable limitations.
First, the study was powered to detect a significant difference between the case and control groups in cumulative caffeine citrate exposure at specified points during a seven-day period before the development of NEC or the index date. In light of our finding that such a difference existed four days before the development of NEC or the index date, it would be reasonable to expect that a similar difference might also exist at two and three days before the development of NEC. That our analysis did not indicate a significant between-group difference at the two-and three-day time points could be due to our study being underpowered to detect a difference at those particular time points; the analyses of mean average caffeine citrate loading doses (n = 25) and average troughs values (n = 86) may not have had adequate power to detect significant differences. Alternatively, as mentioned previously, the finding of a significant difference at the four-day time point may simply have been a coincidence.
Another limitation of the study was the short duration of collection of data on caffeine citrate exposure and other variables in both the NEC and control groups. NEC is a multifactorial disease, and it is possible that we did not account for all potential confounding factors.
In light of the study results, we believe it is likely that there was not an association between NEC development and caffeine citrate exposure during the seven-day period evaluated. However, additional researchincluding multicenter and, preferably, prospective studies-is needed to confirm our findings.
Conclusion
Cumulative exposure to caffeine citrate among infants who developed NEC and infants who did not develop NEC differed significantly at only one of six evaluated time points during the seven days before NEC development or the index date. There was no significant difference between groups in the proportions of patients who received caffeine citrate or in mean serum caffeine concentrations.
